Promotes Charles Huiner to Chief Operating Officer and Senior Vice President of Corporate Development & Strategy
Promotes Chief Financial Officer Matthew Pigeon to Chief Financial Officer and Senior Vice President
SANTA BARBARA, Calif., Feb. 01, 2016 -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the promotion of Charles Huiner to Chief Operating Officer and Senior Vice President of Corporate Development & Strategy, effective immediately. In addition to continuing to lead the Company’s business development and strategy, Mr. Huiner will assume responsibility for Sientra’s manufacturing operations, clinical operations and legal affairs functions.
The Company also announced the promotion of Matthew Pigeon to Senior Vice President in addition to his role as Chief Financial Officer and Treasurer.
Jeffrey Nugent, Chairman and Chief Executive Officer of Sientra, said, “Since joining the Sientra team in 2014, Charlie has demonstrated the ability to think strategically and facilitate a high level of cooperation and execution across the Company. His increased responsibilities at this time are critical to help coordinate the important cross functional priorities we have in front of us, including the ongoing development and execution of our manufacturing and supply chain strategy. Matt’s role in financial planning and control as well as the overall strategic direction of the Company will continue to be critical to our success. We congratulate both Charlie and Matt in their new roles and look forward to their continued contributions.”
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients' lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products.
Investor Contacts: The Ruth Group Nick Laudico / Brandon Vazquez (646) 536-7030 / 7032 [email protected]


Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Robinhood Expands Sports Event Contracts With Player Performance Wagers
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 



